Business Context and Reporting Period
This Form 8-K is filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on August 7, 2018. The filing serves to announce the company's financial results for the second quarter of 2018. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) for these details, but the content of that exhibit is not included in the source text.
Material Changes
No material changes or comparative financial data versus the prior period are detailed in the provided text. The filing solely indicates that Q2 2018 results were announced.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information is "furnished" and not "filed" under Section 18 of the Exchange Act, limiting liability. No specific guidance, outlook, management commentary, or risk factors are present in the text provided.
Investor Verification Checklist
- Verify the correct registrant name: The filing is for Zafgen, Inc., despite the metadata reference to Larimar Therapeutics, Inc.
- Retrieve Exhibit 99.1 (the press release) to obtain actual Q2 2018 financial figures.
- Confirm the company's status as an emerging growth company and any associated accounting election impacts.
- Review the full press release for any forward-looking statements or operational updates not captured in this summary.